Data | Group | Pre-intervention | Post-intervention | 2-way ANOVA p-value |
---|---|---|---|---|
Burst frequency (bursts/min) | Placebo | 31.7 ± 11.0 | 30.0 ± 16.7 | Group = 0.03* Time-point = 0.34 Group x Time-point = 0.63 |
Moxonidine | 25.2 ± 7.9 | 20.0 ± 6.0 | ||
Burst incidence (bursts/100HB) | Placebo | 47.9 ± 13.1 | 46.3 ± 24.1 | Group = 0.02* Time-point = 0.52 Group x Time-point = 0.76 |
Moxonidine | 37.4 ± 10.0 | 32.7 ± 10.1 | ||
Units/min | Placebo | 1624 ± 697 | 1477 ± 989 | Group = 0.03* Time-point = 0.44 Group x Time-point = 0.93 |
Moxonidine | 1162 ± 338 | 977 ± 304 | ||
Units/100HB | Placebo | 2448 ± 877 | 2263 ± 1303 | Group = 0.02* Time-point = 0.54 Group x Time-point = 0.96 |
Moxonidine | 1734 ± 429 | 1578 ± 460 |